Sevda Bayramova

Sevda Bayramova

Auto-generated profile, based on publicly available information

Sevda Bayramova

Meshalkin National Medical Research Center of the Ministry of Health

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2014 in Heart Rhythm
Verified
Journal Article
Closed access
JSJonathan S. Steinberg
Jonathan S. Steinberg
ARAlexander Romanov
Alexander Romanov
DMDan Musat
Dan Musat
MPMark Preminger
Mark Preminger
SBSevda Bayramova
Sevda Bayramova
EPEvgeny Pokushalov
Evgeny Pokushalov

14 August 2018 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
EME. N. Mikhailov
E. N. Mikhailov
NGN. Z. Gasymova
N. Z. Gasymova
SBS. А. Bayramova
S. А. Bayramova
VKV. E. Kharats
V. E. Kharats
OKO. N. Kachalkova
O. N. Kachalkova
ESE. V. Shlyakhto
E. V. Shlyakhto
Aim. The results presented, of subanalysis of the catheter ablation (CA) registry in atrial fibrillation (AF) with the patients properties, specifics of CA and treatment results, in Russia comparing to European countries.Material and methods. During 2012 to 2015, totally 3742 patients included to the registry, of those 477 in Russia. In 467 Russian patients (males 56,5%; mean age 58,5 y. o.) CA AF was done. During one year 392 patients were followed up. Minimum requirements to follow-up: routine ECG registration and non less than one contact after 12 months passed.Results. In Russian patients there were more common obesity (46,1% and 29,2%, p<0,001), hypertension heart disease (40,2% and 22,8%, p<0,0001), coronary heart disease (31,7% and 16,2%, p<0,0001), chronic heart failure (67,3% and 13,0%, p<0,0001). In Russia the patients more commonly underwent primary CA (83,5% in Russia and 77,6% in European countries, p<0,05), more rare in Russia the cryoballoon ablation was done (3% and 18%, p<0,05). Generally adverse events were reported more rare in Russia (10,5% and 16,6%, p=0,0007), including cardiovascular adverse events (2,6% and 5,2%, p<0,05). Tachiarrhythmias recurs were diagnosed more rare in Russia, including by the subsutaneous ECG monitors (17% and 1,6% in other countries, р<0,001). Within the year of follow-up, full absence of tachiarrhythmias recurs in Russia was found in 65,8% of patients, in other countries — in 74,7% (р=0,0003).Conclusion. In real clinical setting, high efficacy of CA AF was shown, resistant to antiarrhythmic therapy. In most of Russian patients there were cardiovascular comorbidities. There was lower rate of reported adverse events in Russian centers of interventional treatments.

8 June 2020 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
EMEvgeny N Mikhaylov
Evgeny N Mikhaylov
LKL. E. Korobchenko
L. E. Korobchenko
SBS. A. Bayramova
S. A. Bayramova
VKV. E. Kharats
V. E. Kharats
OKO. N. Kachalkova
O. N. Kachalkova
ЕМЕ. Н Михайлов
Е. Н Михайлов
Aim. Catheter ablation (CA) is an effective approach for rhythm control in atrial fibrillation (AF), however antiarrhythmic therapy (AAT) remains important. There is a lack of data about long-term AAT use after CA. This study evaluates AAT after CA for AF.Material and methods. In 2012-2016, EURObservational Research Programme of Atrial Fibrillation Ablation Long-Term (EORP AFA L-T) registry was conducted, which included 476 Russian patients (57,1% — men; mean age — 57,1±8,7 years). The follow-up after CA was 12 months (available in 81,9% of patients). The use of AAT was evaluated prior to hospitalization, during hospitalization for CA, as well as at 3, 6 and 12 months of follow-up.Results. Prior to CA, 439 (92,2%) patients received AAT During CA, 459 (96,4%) patients were treated with AAT. After CA, AAT was used by 463 (97,3%), 370 (94,8%), and 307 (78,7%) patients at 3, 6 and 12 months of follow-up, respectively. There was no arrhythmia recurrence in 187 (47,9%) subjects. Among these patients, 40 (21,4%) received class IC or III AAT. The peak of AAT use was found for class IC agents within 3 months after CA (P<0,05), while for other drugs this trend was not observed. There were no factors associated with AAT usage in patients without arrhythmia recurrence after CA. A positive correlation of arrhythmia non-recurrence with a minimum number of previously used antiarrhythmic agents was revealed (RR=0,85; 95% CI 0,73-0,98; P=0,03).Conclusion. The frequency of AAT use after AF ablation is significantly reduced. However, there is a cohort of patients without documented arrhythmia recurrence still receiving AAT, which requires special attention of physicians. There were no clinical predictors of continued AAT in subjects without arrhythmia recurrence.

1 April 2014 in JACC
Verified
Journal Article
Closed access
EPEvgeny Pokushalov
Evgeny Pokushalov
ARAlexander Romanov
Alexander Romanov
DKDemosthenes Katritsis
Demosthenes Katritsis
SASergey Artyomenko
Sergey Artyomenko
SBSevda Bayramova
Sevda Bayramova
JSJonathan Steinberg
Jonathan Steinberg

1 April 2016 in JACC
Verified
Journal Article
Closed access
EPEvgeny Pokushalov
Evgeny Pokushalov
ARAlexander Romanov
Alexander Romanov
DKDemosthenes Katritsis
Demosthenes Katritsis
ASArtem Strelnikov
Artem Strelnikov
SASergey Artemenko
Sergey Artemenko
JSJonathan Steinberg
Jonathan Steinberg